These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12199266)

  • 1. Venous thrombosis with cyproterone.
    Prescrire Int; 2002 Aug; 11(60):116. PubMed ID: 12199266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thrombosis with cyproterone (continued).
    Prescrire Int; 2004 Apr; 13(70):59. PubMed ID: 15148982
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
    Vasilakis-Scaramozza C; Jick H
    Lancet; 2001 Oct; 358(9291):1427-9. PubMed ID: 11705493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific oral contraceptive use and venous thromboembolism resulting in hospital admission.
    Heuser P; Tonga K; Hopkins R; Henderson M; Weatherall M; Metcalfe S; Beasley R
    N Z Med J; 2004 Nov; 117(1206):U1176. PubMed ID: 15570345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-use risks.
    Rowe TC
    CMAJ; 2003 May; 168(11):1394. PubMed ID: 12771065
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk of venous thromboembolism and oral contraceptives.
    Gompel A; Carpentier S; Francès C; Piette JC
    Lancet; 2002 Apr; 359(9314):1348-9. PubMed ID: 11965310
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of an anti-androgen combination preparation on the hemostatic system].
    Bruni V; Rosati D; Bucciantini S; Verni A; Abbate R; Pinto S; Costanzo G; Costanzo M
    Fortschr Med; 1987 Jan; 105(3):55-8. PubMed ID: 3557259
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
    van Vliet HA; Frolich M; Christella M; Thomassen LG; Doggen CJ; Rosendaal FR; Rosing J; Helmerhorst FM
    Hum Reprod; 2005 Feb; 20(2):563-8. PubMed ID: 15539435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Why splash a well-known adverse effect as a news?].
    Brynhildsen J; Danielsson KG
    Lakartidningen; 2007 Jan 31-Feb 6; 104(5):355-6; author reply 356. PubMed ID: 17330334
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hormonal contraception and venous thrombosis].
    Lidegaard Ø
    Ugeskr Laeger; 2013 May; 175(20):1401. PubMed ID: 23663393
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormonal contraception: recent advances.
    Szarewski A
    J Fam Health Care; 2006; 16(2):35-6. PubMed ID: 16715750
    [No Abstract]   [Full Text] [Related]  

  • 14. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Axillary vein thrombosis in a young woman with a contraceptive ring. Prothrombin gene mutation a possible connection].
    Samuelsson E; Hultdin J; Groth K; Hedenmalm K
    Lakartidningen; 2007 Jan 10-16; 104(1-2):32-4. PubMed ID: 17323737
    [No Abstract]   [Full Text] [Related]  

  • 16. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors.
    Tanis BC; Rosendaal FR
    Semin Vasc Med; 2003 Feb; 3(1):69-84. PubMed ID: 15199494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some new psychological side effects due to anti-androgenic properties of cyproterone compound.
    Eftekhari P; Raoufy MR; Gharibzadeh S
    Med Hypotheses; 2007; 68(6):1422-3. PubMed ID: 17222520
    [No Abstract]   [Full Text] [Related]  

  • 18. Levonorgestrel-releasing intra-uterine systems (LNG-IUS) and breast cancer.
    Neven P; Amant F; Poppe W; Van den Broecke R
    Fertil Steril; 2009 Apr; 91(4):e5; author reply e6. PubMed ID: 19249759
    [No Abstract]   [Full Text] [Related]  

  • 19. Fulminant liver failure caused by cyproterone.
    Famularo G; Minisola G; Grieco A; Miele L
    Dig Liver Dis; 2005 Sep; 37(9):718-9. PubMed ID: 15936995
    [No Abstract]   [Full Text] [Related]  

  • 20. [The influence of antiandrogens on the development of vaginal candidosis (author's transl)].
    Farkas B; Simon N
    Mykosen; 1981 Apr; 24(4):203-8. PubMed ID: 6456411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.